Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

Research output: Contribution to journal › Research article › Contributed › peer-review

Contributors

  • A. Du Bois - (Author)
  • G. Kristensen - (Author)
  • I. Ray-Coquard - (Author)
  • A. Reuss - (Author)
  • S. Pignata - (Author)
  • N. Colombo - (Author)
  • U. Denison - (Author)
  • I. Vergote - (Author)
  • J.M. Del Campo - (Author)
  • P. Ottevanger - (Author)
  • M. Heubner - (Author)
  • T. Minarik - (Author)
  • E. Sevin - (Author)
  • N. De Gregorio - (Author)
  • M. Bidzinski - (Author)
  • J. Pfisterer - (Author)
  • S. Malander - (Author)
  • F. Hilpert - (Author)
  • M.R. Mirza - (Author)
  • G. Scambia - (Author)
  • W. Meier - (Author)
  • M.O. Nicoletto - (Author)
  • L. Bjørge - (Author)
  • A. Lortholary - (Author)
  • M.O. Sailer - (Author)
  • M. Merger - (Author)
  • P. Harter - (Author)
  • AGO Study GrOup Led GynecOLOgic Cancer IntergrOup/ - (Author)
  • U. Canzler - , Department of Gynecology and Obstetrics (Author)
  • P. Wimberger - , Department of Gynecology and Obstetrics (Author)

Details

Original languageEnglish
Pages (from-to)78-89
Number of pages12
JournalThe Lancet Oncology
Publication statusPublished - 2016
Peer-reviewedYes

External IDs

Scopus 84955299214

Keywords

Sustainable Development Goals